Pulmonary Surfactant Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-27　·　168 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 723.2 Mn
2033 年預估規模: USD 947.8 Mn
年複合成長率 CAGR: 7.2%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-27頁數 168報告編號 CMI5324

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Pulmonary Surfactant Market, By Type (Synthetic Pulmonary Surfactant, Animal Derived Surfactant), By Drug Type (Poractant alfa, Lucinactant, Calfactant), By Indications (Respiratory Distress Syndrome (RDS), Respiratory Infections, Obstructive lung Diseases, Others (chronic lung disease of prematurity, and surfactant protein-B deficiency)), By Route of Administration (Intratracheal, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

Pulmonary surfactant is a complex and highly surface active material composed of lipids and proteins which is found in the fluid lining the alveolar surface of the lungs. Surfactant plays a vital role in pulmonary physiology. It’s major biophysical functions is to prevent alveolar collapse at low lung volume and to preserve bronchiolar patency during normal and forced respiration, and it’s major non biophysical, immunological, functions is protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms. Pulmonary surfactant is heterogeneous with respect to biochemical composition, morphological organization and specific biophysical functions. Surfactant prevents alveolar collapse at low lung volume, and preserves bronchiolar patency during normal and forced respiration (biophysical functions). In addition, it is involved in the protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms (immunological, non-biophysical functions). Pulmonary surfactant can only be harvested by lavage procedures, which may disrupt its pre-existing biophysical and biochemical micro-organization. These limitations must always be considered when interpreting ex vivo studies of pulmonary surfactant. Market Dynamics Increasing rate of prevalence of several respiratory infection and respiratory is expected to drive the global pulmonary surfactant market over the forecast period. For instance, on May 20, 2022, 90% of COPD (Chronic obstructive pulmonary disease) deaths were reported globally, in those under 70 years of age occur in low- and middle-income countries (LMIC) such as India, Korea and Bangladesh. Chronic obstructive pulmonary disease (COPD) is one of the major cause of death worldwide, causing 3.23 million deaths in 2019. Increasing drug approvals for novel therapeutic agents are some of the key factors driving the global pulmonary surfactant market growth. For instance, in July 2020, Boehringer Ingelheim, a pharmaceutical company, announced that the European Commission (EC) approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020. The U.S. Food and Drug Administration (FDA), Health Canada and the Japan based pharmaceuticals and Medical Devices Agency (PMDA) approved nintedanib as the treatment for the same patient population. The approval is based on the results of INBUILD, which was a randomized, double-blind, placebo-controlled, parallel-group phase III trial, which evaluated the efficacy, safety, and tolerability of nintedanib in patients with chronic fibrosing ILDs with a progressive phenotype. Key features of the study • This report provides an in-depth analysis of the global pulmonary surfactant market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players • It profiles leading players in the global pulmonary surfactant market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans. • Key companies covered as a part of this study include, Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics • The global pulmonary surfactant market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts. • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pulmonary surfactant Market Segmentation • By Type o Synthetic Pulmonary Surfactant o Animal Derived Surfactant • By Drug Type o Poractant alfa o Lucinactant o Calfactant • By Indications o Respiratory Distress Syndrome (RDS) o Respiratory Infections o Obstructive lung Diseases o Others (chronic lung disease of prematurity, and surfactant protein-B deficiency) • By Route of Administration o Intratracheal o Injectable • By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Regional Insights o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Boehinger Ingelheim o AbbVie Inc o Chiesi Farmaceutici o ONY Biotech Inc. o Lyomark Pharma o Abbott o Aviva Systems Biology Corporation o Windtree Therapeutics, Inc o Tekzima (Noargen) o Biomatik o Nanjing Norris Pharm Technology o Reddot Biotech

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Type  Market Snapshot, By Drug Type  Market Snapshot, By Indications  Market Snapshot, By Route of Administration  Market Snapshot, By Distribution Channel  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Drivers o Restraints o Market Opportunities o Impact Analysis o Market Trends o Key Developments o Regulatory Scenario o Industry Trend o New Product Approvals/Launch o Merger and Acquisitions o PEST Analysis 4. Global Pulmonary Surfactant Market, By Type, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Synthetic Pulmonary Surfactant  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Animal Derived Surfactant  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 5. Global Pulmonary Surfactant Market, By Drug Type, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Poractant alfa  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Lucinactant  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Calfactant  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 6. Global Pulmonary Surfactant Market, By Indications, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Respiratory Distress Syndrome (RDS)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Respiratory Infections  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Obstructive lung Diseases  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 7. Global Pulmonary Surfactant Market, By Route of Administration, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Intratracheal  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Injectable  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 8. Global Pulmonary Surfactant Market, By Distribution Channel, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Hospital Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Retail Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Online Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 9. Global Pulmonary Surfactant Market, By Region, 2026 – 2033, (USD Million) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2021-2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million) o UK o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million) o North Africa o Central Africa o South Africa 10. Competitive Landscape o Heat Map Analysis o Company Profile  Boehringer Ingelheim o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  AbbVie Inc. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Chiesi Farmaceutici o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  ONY Biotech Inc. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Lyomark Pharma o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Abbott o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Aviva Systems Biology Corporation o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Windtree Therapeutics, Inc o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Tekzima (Noargen) o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Biomatik o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Nanjing Norris Pharm Technology o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Reddot Biotech o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies o Analyst Views 11. Section o References o Research Methodology o About Us

提及公司

Boehinger IngelheimAbbVie IncChiesi FarmaceuticiONY Biotech Inc.Lyomark PharmaAbbottAviva Systems Biology CorporationWindtree Therapeutics, IncTekzima (Noargen)BiomatikNanjing Norris Pharm TechnologyReddot Biotech

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們